ENA Workshop Marseille 2015

All sessions will be held in the Auditorium, except for the “Meet the Experts” sessions.

Thursday, December 10th, 2015

11:45-13:00  Satellite symposium 1: sponsored by NOVARTIS
Case by case: an individualized approach to the treatment of acromegaly
A lunch buffet will be offered by NOVARTIS after the symposium, for the symposium attendees
Programme chair: Diego Ferone
Case presenters: Maria Fleseriu, Ilan Shimon
G-SOM-1117367
Welcome and introduction  Diego Ferone, Italy
Case 1: Diagnosis, initial treatment and monitoring  Maria Fleseriu, United States
Case 2: Patient with inadequately controlled acromegaly  Ilan Shimon, Israel
Symposium conclusion and close  Diego Ferone, Italy

13:00-13:30  Break

13:30-14:30  Workshop opening and ENEA Studies
Chairpersons: Annamaria Colao, Ilan Shimon
Workshop opening  Thierry Brue, France
AMORE  Annamaria Colao, Italy
HEROS  Ilan Shimon, Israel
MAPPY  Frederic Castinetti, France

14:30-16:00  Symposium 1: Novel mechanistic insights and therapeutic targets
Chairpersons: Clara Alvarez, Alain Enjalbert
Zebrafish, a new model to study pituitary tumors  Giovanni Vitale, Italy
Regulation of GH synthesis in the pituitary  Marily Theodoropoulou, Germany
Modelization of signal transduction in pituitary cells  David Romano, France

16:00-16:30  Break, visit to posters and exhibition

16:30-18:00  Symposium 2: Involvement of AIP and other genes in somatotropinomas
Chairpersons: Anne Barlier, Jacques Drouin
Insights from whole-genome sequencing of somatotropinomas  Niko Välimäki, Finland
AIP and tumorigenesis  Marie-Lise Jaffrain-Rea, Italy
Experimental characteristics of mutant AIP proteins  Marta Korbonits, United Kingdom
18:15-19:00  **Controversy: is radiotherapy indicated in acromegaly?**  
*Chairpersons: Albert Beckers, Marija Pfeifer*

Case for radiotherapy  
John Ayuk, United Kingdom

Case against radiotherapy  
Frederic Castinetti, France

19:00-19:30  **Rolf Gaillard Award lecture**  
*Chairperson: Philippe Chanson*

The promise of translational research in pituitary tumors  
Günter Stall, Germany

---

**Friday, December 11th, 2015**

08:15-09:15  **Plenary lectures 1 & 2**  
*Chairperson: Sabina Zacharieva*

Acromegalogigantism  
Albert Beckers, Belgium

Is acromegaly a risk factor for cancer?  
Vera Popovic, Serbia

09:15-10:45  **Symposium 3: Genetics of acromegaly**  
*Chairpersons: Marta Korbonits, Marek Bolanowski*

Alterations of the cAMP pathway in acromegaly  
Anna Spada, Italy

MEN1 in young patients  
Pierre Goudet, France

p27 mutations and syndromic pituitary adenomas  
Natalia Pellegata, Germany

10:45-11:15  **Break, visit to posters and exhibition**

11:15-12:15  **Oral communications**  
*Chairpersons: Monica Gadelha, Adrian Daly*

AUDITORIUM

- Incidence, multi-morbidity and long-term prognosis of acromegaly  
  Jakob Dal, Denmark
- REMAH, the spanish molecular registry of pituitary adenomas: focus on acromegaly  
  Justo P Castano, Spain
- Interrelation of the sleep breathing disorders and hypertension in patients with acromegaly  
  Alexander Dreval, Russia
- The partner perspective of the impact of acromegaly: results from a focus group study  
  Cornelia Andela, The Netherlands
- Correlation between biochemical and clinical markers of remission in acromegaly  
  Tatjana Isailovic, Serbia

**Meet the Experts**

ROOM 92

- Challenging cases in acromegaly  
  Diego Ferone, Italy

ROOM 120

- GH receptor antagonists in acromegaly  
  Peter Trainer, United Kingdom

12:15-13:00  **Lunch buffet, visit to posters and exhibition**
13:00-14:15  **Satellite symposium 2: sponsored by PFIZER**  
**Towards disease control in acromegaly: comorbidities and key considerations**  
*Chair: John Wass*  
EBT/SOM/15/34

- Welcome and introduction  
  John Wass, United Kingdom
- Acromegaly, diabetes and cardiovascular complications  
  Sebastian Neggers, The Netherlands
- Acromegaly and sleep apnoea  
  Ken Ho, Australia
- Acromegaly and musculoskeletal problems  
  Ariel Barkan, United States
- Panel discussion, summary and close  
  John Wass, United Kingdom

14:15-15:00  **Poster session**  
*Chairpersons: Maria Tichomirowa, Diego Ferone*

15:00-16:30  **Symposium 4: Treatment challenges**  
*Chairpersons: Elena Grineva, André Lacroix*

- Should surgery be first line?  
  Michael Buchfelder, Germany
- What place for combination therapy in acromegaly?  
  Sebastian Neggers, The Netherlands
- Treatment goals: a critical review  
  Philippe Chanson, France

16:30-17:00  **Break, visit to posters and exhibition**

17:00-18:00  **ENEA Young Investigators Research Committee (EYRC) Symposium**  
*Chairpersons: Gianluca Tamagno, Frederic Castinetti*

- Effects of ursodeoxycholic acid therapy on cholelithiasis prevention  
  in acromegalic patients treated with somatostatin analogs  
  Ludovica F Stella Grasso, Italy
- Impact of pegvisomant on both hormonal secretion and proliferation  
  of human GH-secreting pituitary adenomas: an in vitro study  
  Thomas Cuny, France
- X-linked acrogigantism (X-LAG): results from a large cohort of patients  
  with pituitary gigantism  
  Donato Iacovazzo, United Kingdom
- The AHR repressor expression correlates with the in vitro  
  aggressiveness of a cellular model of GH-secreting pituitary adenoma  
  Daniela Regazzo, Italy
- Hypoxia-inducible factor 1α triggers growth hormone synthesis  
  in acromegalic tumors  
  Kristin Lucia, Germany
- A look from the EYES  
  Sanne E Franck, The Netherlands

18:00-19:15  **Satellite Symposium 3: sponsored by IPSEN**  
**Finding a route to improve patient management in acromegaly**  
*Chair: Philippe Caron*  
SOM-FR-000459 – 10/2015

- Introduction  
  Philippe Caron, France
- Optimising patient characterisation via clinical and biochemical assessment  
  Philippe Chanson, France
- Optimising decision-making in acromegaly to improve long term outcomes  
  Mark Gurnell, United Kingdom
- Conclusions and close  
  Philippe Caron, France

20:00  **Workshop Dinner (Eugénie Room, Palais du Pharo)**
Saturday, December 12th, 2015

08:30-09:30  Plenary lectures 3 & 4
Chairperson: Günter Stalla
“Micromegaly”, myth or reality? Ariel Barkan, United States
Unusual comorbidities of acromegaly Annamaria Colao, Italy

09:30-11:00  Symposium 5: Predictive markers of treatment response
Chairpersons: Manuel Gahete, Gregory Kaltsas
Biological markers Jens Otto Jorgensen, Denmark
Clinical and immunohistochemical markers Jens Bollerslev, Norway
Radiological markers Jean-François Bonneville, France

11:00-11:30  Break, visit to posters and exhibition

11:30-13:00  Symposium 6: Resistance to somatostatin analogues (SA)
Chairpersons: Marily Theodoropoulou, Alberto Pereira
Somatostatin receptor 5 isoforms in SA resistance Raul Luque, Spain
Somatostatin receptor trafficking and SA resistance Federico Gatto, Italy
How to manage SA resistance? Monica Gadelha, Brazil

13:00-13:30  Poster prizes, Workshop closing  Thierry Brue, France

POSTERS

<table>
<thead>
<tr>
<th>Title</th>
<th>Presenter</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P01 Malignant paraganglioma and acromegaly: new spectrum of SDHB mutations</td>
<td>Ana Saavedra</td>
<td>Ana Saavedra</td>
</tr>
<tr>
<td>P02 Disturbance of the GNAS locus imprinting in human somatotroph adenomas</td>
<td>Pauline Romanet</td>
<td>Pauline Romanet</td>
</tr>
<tr>
<td>P03 Adrenal insufficiency in acromegaly</td>
<td>Filippo Ceccato</td>
<td>Filippo Ceccato</td>
</tr>
<tr>
<td>P04 Are invasive GH-producing pituitary adenomas clinically and molecularly different?</td>
<td>Alfonso Soto</td>
<td>Alfonso Soto</td>
</tr>
<tr>
<td>P05 Impact of the GH-receptor antagonist pegvisomant on mammographic breast density in postmenopausal acromegalic women</td>
<td>Federico Gatto</td>
<td>Federico Gatto</td>
</tr>
<tr>
<td>P06 Thymus tumour in an acromegalic male with newly discovered type 1 polyglandular autoimmune syndrome</td>
<td>Mara Carsote</td>
<td>Mara Carsote</td>
</tr>
<tr>
<td>P07</td>
<td>Dissociated response to octreotide and pasireotide in an acromegalic patient with pituitary macroadenoma</td>
<td>Elena Nazzari Italy</td>
</tr>
<tr>
<td>P08</td>
<td>Acromegaly secondary to aggressive pituitary tumor in a patient with MEN-1</td>
<td>Elena Nazzari Italy</td>
</tr>
<tr>
<td>P10</td>
<td>X-linked Acro-gigantism (X-LAG) Syndrome: Two New Cases with Long-term Follow-up</td>
<td>Adrian Daly Belgium</td>
</tr>
<tr>
<td>P11</td>
<td>Screening for germline GPR101 and AIP mutations in patients with sporadic pituitary adenomas</td>
<td>Peter Kamenicky France</td>
</tr>
<tr>
<td>P12</td>
<td>Primary treatment with Somatostatin Analogues does not change MRI T2 image characteristics in treatment naïve patients with acromegaly</td>
<td>Ansgar Heck Norway</td>
</tr>
<tr>
<td>P13</td>
<td>Successful Pregnancy in Acromegalic Patient</td>
<td>Suleyman Nahit Sendur Turkey</td>
</tr>
<tr>
<td>P14</td>
<td>Spine bone texture assessed by trabecular bone score (TBS) to evaluate bone quality in acromegaly</td>
<td>Elena Malchiodi Italy</td>
</tr>
<tr>
<td>P15</td>
<td>High precision conformal fractionated radiotherapy is effective in achieving remission in patients with acromegaly after failed transsphenoidal surgery</td>
<td>Jugal Gada India</td>
</tr>
<tr>
<td>P16</td>
<td>Surgical outcomes of short-term preoperative treatment with octreotide LAR in Korean acromegals</td>
<td>Sang Ouk Chin Rep of South Korea</td>
</tr>
<tr>
<td>P17</td>
<td>Features of postmenopause in women with acromegaly</td>
<td>Irena Ilovayskaya Russian Federation</td>
</tr>
<tr>
<td>P18</td>
<td>Pituitary tumor mass effect in somatotropinomas</td>
<td>Yulia Krivosheeva</td>
</tr>
<tr>
<td>P19</td>
<td>Gastrointestinal tract changing in acromegalic patients</td>
<td>Yulia Pokramovich</td>
</tr>
<tr>
<td>P20</td>
<td>Role of mTOR and ERK 1/2 pathways in regulating GH secretion in rat pituitary adenoma cell line</td>
<td>Carmelina Di Pasquale</td>
</tr>
<tr>
<td>P21</td>
<td>Immune status indices and chemiluminescence activity of blood neutrophils in acromegaly</td>
<td>Margarita Dudina</td>
</tr>
<tr>
<td>P22</td>
<td>Cases of Acromegaly Associated with Multiple Malignant Tumors</td>
<td>Nafiye Helvaci</td>
</tr>
<tr>
<td>P23</td>
<td>Efficacy of radiotherapy in acromegaly</td>
<td>Adliya Kholikova</td>
</tr>
<tr>
<td>P24</td>
<td>High-resolution spatiotemporal analysis of SST2 - FLNA interaction by single-molecule imaging</td>
<td>Donatella Treppiedi</td>
</tr>
<tr>
<td>P25</td>
<td>Effects of long-term combined treatment with somatostatin analogs and pegvisomant on cardiac structure and performance in acromegaly</td>
<td>Renata Simona Aurieamma</td>
</tr>
<tr>
<td>P26</td>
<td>The short-term efficacy and complication rate of pituitary irradiation in patients with acromegaly: a comparison of conventional and fractionated stereotactic radiotherapy</td>
<td>Hanna Tuinhof</td>
</tr>
<tr>
<td>P27</td>
<td>Acromegaly. What do we have indeed?</td>
<td>Farida Nasybullina</td>
</tr>
<tr>
<td>P28</td>
<td>Somatostatin analogues in the long-term treatment of acromegaly - comparison of their efficacy in primary and secondary therapy</td>
<td>Natalia Zawada</td>
</tr>
<tr>
<td>P29</td>
<td>Effect of transsphenoidal surgery or combined treatment on sleep apnea and twenty-four hour profile of blood pressure in patients with active acromegaly</td>
<td>Uliana Tsoy</td>
</tr>
<tr>
<td>P30</td>
<td>Symptoms and comorbidities at diagnosis of 472 acromegalic patients diagnosed between 2009 and 2014</td>
<td>Philippe Caron</td>
</tr>
<tr>
<td>P31</td>
<td>Acromegalic arthropathy in various stages of the disease: a Magnetic Resonance Imaging (MRI) study</td>
<td>Kim Claessen</td>
</tr>
<tr>
<td>P32</td>
<td>More concerns and stronger beliefs about the necessity of medication in patients with acromegaly associate with negative illness perceptions and impairment in Quality of Life</td>
<td>Cornelie Andela</td>
</tr>
<tr>
<td>P33</td>
<td>The incidence of thyroid cancer in patients with acromegaly</td>
<td>Natalya Molitvoslovova</td>
</tr>
<tr>
<td>P34</td>
<td>Control of hypersecretion only partially restores normal health status in patients with acromegaly</td>
<td>Claire Rochette</td>
</tr>
<tr>
<td>P35</td>
<td>Involvement of the constitutive activity of the GHS-R1a (ghrelin G-protein coupled receptor) in the tumorigenesis of somatotroph adenomas</td>
<td>Sylvie Thirion</td>
</tr>
<tr>
<td>P36</td>
<td>Body image perception in acromegaly is not associated with objective acromegalic changes, but depends on depressive symptoms</td>
<td>Christina Dimopoulou</td>
</tr>
<tr>
<td>P37</td>
<td>Acromegaly accompanied by five other neoplasms</td>
<td>Aleksandra Jawiarczyk</td>
</tr>
<tr>
<td>P38</td>
<td>Growth hormone suppression in the glucose tolerance test: is the cut-off of &lt;0.4 ng/ml always sufficient: a case report</td>
<td>Katharina Schilbach</td>
</tr>
<tr>
<td>P39</td>
<td>Blindness and hydrocephalus due to a tuberculum sellae meningioma</td>
<td>Guillermo Serra</td>
</tr>
<tr>
<td>P41</td>
<td>A case of acromegaly and disseminated follicular thyroid carcinoma</td>
<td>Agata Baldys-Waligorska</td>
</tr>
<tr>
<td>P42</td>
<td>Macroprolactinomas: clinical features, management and outcomes</td>
<td>Imen Rojbi</td>
</tr>
<tr>
<td>P43</td>
<td>Mild increase in GH secretion but no gigantism or pituitary adenoma development in young and middle-aged Aip-deficient male mice</td>
<td>Anne-Lise Lecoq</td>
</tr>
<tr>
<td>P44</td>
<td>Acromegaly double trouble in an AIP-positive R304X man from Bangladesh</td>
<td>Ann Mccormack</td>
</tr>
</tbody>
</table>